Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924624 | 0.81 | TLR8 (0.38) | TLR8TLR7PRMT5 | |
| SCHEMBL8133953 | 0.77 | TLR8 (0.41) | TLR8TLR7PRMT5KDM4EMEN1 | |
| SCHEMBL3355697 | 0.73 | TLR8 (0.36) | TLR8TLR7PRMT5KDM4EHSP90AA1 | |
| SCHEMBL301016 | 0.72 | TLR8 (0.38) | TLR8TLR7PRMT5KDM4EMAPT | |
| SCHEMBL13914459 | 0.70 | KDM4E (0.36) | TLR8TLR7PRMT5KDM4EMEN1 | |
| SCHEMBL3673936 | 0.69 | CYP3A4 (0.34) | — | |
| SCHEMBL5513106 | 0.69 | TLR8 (0.41) | TLR8TLR7PRMT5KDM4EHSP90AA1 | |
| SCHEMBL202692 | 0.69 | RAB9A (0.52) | KDM4EMEN1MAPTHTTKMT2A | |
| SCHEMBL22595963 | 0.68 | PRMT5 (0.47) | PRMT5KDM4EMEN1LMNAHSP90AA1 | |
| SCHEMBL204153 | 0.67 | KDM4E (0.44) | PRMT5KDM4EMEN1LMNAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212093-A1 | Viricides, antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212093-A1 | Viricides, antitumor agents | IFNG, IFNAR1, MAVS | TLR8 292/4885TLR7 116/4885PRMT5 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.